

Date: 6th May, 2024

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code:533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Alembic Pharmaceuticals Limited received an Establishment Inspection Report (EIR) for its Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav.

Ref.: Our earlier intimation dated 8th March, 2024 - US FDA Inspection at Alembic Pharmaceuticals Limited's Oncology (Injectable and Oral Solid) Formulation Facility at Panelav.

We are pleased to inform the exchanges that the Company has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for the inspection carried out by them at our Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav from 28th February, 2024 to 8th March, 2024.

With this, for all our USFDA facilities, EIRs are in place.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED